IPP Bureau
UK journal publishes complex case of severe pan-drug resistant infection in US liver transplant patient successfully treated with Zaynich
By IPP Bureau - July 28, 2025
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
Akums’ Haridwar factory receives ANVISA GMP certification for sterile manufacturing plant
By IPP Bureau - July 28, 2025
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
GSK forges $12 billion alliance with Hengrui Pharma
By IPP Bureau - July 28, 2025
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Dr. Reddy’s re-appoints G V Prasad as Co-Chairman and Managing Director
By IPP Bureau - July 27, 2025
Prasad has played a key role in shaping Dr. Reddy’s into a globally respected organisation
Granules India CEO K V Sitaram Rao resigns
By IPP Bureau - July 27, 2025
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Sigachi Industries reports Q1 FY26 consolidated loss at Rs. 100.35 Cr
By IPP Bureau - July 27, 2025
Sigachi Industries has reported total income of Rs. 132.18 crores during the period ended June 30, 2025
EMA’s CHMP recommends authorization of Moderna's Covid-19 vaccine Spikevax for SARS-CoV-2 Variant LP.8.1
By IPP Bureau - July 27, 2025
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
Laurus Labs to invest €5 million in JV KRKA Pharma
By IPP Bureau - July 27, 2025
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
RPG Life Sciences appoints Deepak Shukla as Chief Executive - API Business
By IPP Bureau - July 27, 2025
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Alembic Pharmaceuticals announces USFDA final approval for Carbamazepine ER Tablets USP
By IPP Bureau - July 27, 2025
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Concord Biotech successfully completes Russian GMP inspection at its API facility
By IPP Bureau - July 27, 2025
The inspection was conducted from July 22-25, 2025
Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%
By IPP Bureau - July 27, 2025
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Dr. Reddy’s infuses Rs. 565 crore in its Russian subsidiary
By IPP Bureau - July 27, 2025
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
Laurus Labs consolidated Q1 FY2026 PAT at Rs. 163.02 Cr
By IPP Bureau - July 26, 2025
Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025
